ISRG vs NVO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ISRG exhibits a stable deterministic health profile with a Piotroski F-Score of 4/9 and an exceptionally strong balance sheet (Debt/Equity 0.01). While the company is a fundamental powerhouse with 66% gross margins and consistent earnings beats, it trades at a massive premium to its Graham Number ($94.28) and Intrinsic Value ($232.16). The disconnect between the high valuation (P/E 59.16) and the current price suggests the stock is priced for perfection, leaving little room for error despite strong 18.8% revenue growth.
NVO presents a dichotomy between elite profitability and deteriorating growth. The Piotroski F-Score of 4/9 indicates stable but non-improving financial health, while the current price of $42.22 trades at a significant premium to both the Graham Number ($23.58) and Intrinsic Value ($25.27). Despite an exceptional ROE of 60.7% and strong margins, the company is facing negative YoY revenue (-7.6%) and earnings growth (-4.7%), resulting in a high PEG ratio of 4.53. The outlook is tempered by a bearish technical trend and liquidity concerns, though supported by a strong dividend profile and analyst 'Buy' ratings.
Compare Another Pair
Related Comparisons
ISRG vs NVO: Head-to-Head Comparison
This page compares Intuitive Surgical, Inc. (ISRG) and Novo Nordisk A/S (NVO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.